Attana inks microsampling collaboration with Capitainer for improved diagnostic sampling

Combining Attana’s advanced biosensor system with Capitainer’s DBS home sampling makes immune profiling and vaccine efficacy monitoring possible in broad patient populations.

Swedish bio- and healthtech companies Attana AB and Capitainer AB have signed an agreement with the goal of offering broader and more patient-centric blood sampling solutions for the Attana AVA^TM system starting with COVID-19 immune profiling.

Since November 2021, Attana has been performing comparative studies of finger stick capillary blood samples simultaneously collected by both test tubes and Capitainer®qDBS cards (quantitative dried blood spot) for analysis in Attana's AVA^TM system. These serological studies have shown high specificity and sensitivity with good reproducibility for both sampling methods.

Because of the ease of use and sampling accuracy, Attana and Capitainer have now initiated a collaboration to clinically validate Capitainer's patented qDBS cards in combination with the Attana CE IVD-marked SARS-CoV-2 Immunoassay kit. In the coming months, the parties intend to perform an expanded patient study within the framework of Attana's ongoing Covid study with Linnaeus University and Region Kalmar. The objective is to expand Attana´s CE IVD marking to include sampling of capillary blood (qDBS and test tubes), in addition to current serum samples.

The combination of Capitainer®qDBS and the AVA^TM platform enables distributed, simple, and quality-assured sampling for information rich immunity profiling by combining two innovative Swedish technologies. The patented Capitainer collection device offers blood sampling of exact volumes, which is of great importance in quantitative antibody analyses where the amount of antibodies in a sample is to be measured. Since the Capitainer cards are designed for patient self-sampling, they allow for blood sampling to be carried out over wider geographies and with greater frequency, without significantly affecting sampling costs.

Samir Fostock, Head of Attana Diagnostics comments:

"During the pandemic, standard diagnostic sampling has been particularly challenging in patient studies which call for multiple testing, often also across wide geographic areas. In addition to an ongoing need for COVID-19 immunity and vaccine efficacy studies, there is much to suggest that the need for remote sampling will continue to grow in the coming years within clinical diagnostics, drug development, as well as in academic research fields such as immunology and virology. The Attana AVA system in combination with Capitainer qDBS will be able to offer our customers and their patients high quality diagnostic analyses in a wider scope of studies than possible today."

Mikael Ström, Business Development Manager Capitainer adds:

"Capitainer's solution for quantitative self-sampling enables clinical standard blood samples to be easily taken at home and sent by regular mail to the laboratory for analysis. During the pandemic our sampling solution was validated in several studies and there is a large demand for new analyses which are performed using small sample volumes. The Attana AVA system offers advanced diagnostics and is an ideal fit with Capitainer's ambition to develop analysis solutions from samples that can be taken at home. This collaboration will help to make these new analyses available to patients irrespective of how far they live from a laboratory."

For more information, please contact:

Teodor Aastrup, CEO
teodor.aastrup@attana.com
+46 (0)8 674 57 00

The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share price but is of general interest for the shareholders and hence should be communicated.

About Attana

Attana was founded in 2002 with the vision of in vitro characterization of molecular interactions mimicking in vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays and the Attana Virus Analytics (AVA) platform, a proprietary in vitro diagnostics (IVD) tool. Attana products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about our latest services and products, please visit www.attana.com or contact sales@attana.com

Tags: